Oxford Asset Management’s Integra LifeSciences IART Stock Holding History

Oxford Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,829	Closed	-$1.1M	–	714
2019 Q4	$1.1M	Buy	18,829 +5,079	+37%	+$302K	0.03%	808
2019 Q3	$826K	Buy	+13,750	New	+$819K	0.02%	1034
2016 Q2	–	Sell	-112,646	Closed	-$3.79M	–	831
2016 Q1	$3.79M	Sell	112,646 -1,200	-1%	-$37.4K	0.11%	236
2015 Q4	$3.89M	Sell	113,846 -61,964	-35%	-$1.94M	0.09%	239
2015 Q3	$5.24M	Sell	175,810 -147,220	-46%	-$4.6M	0.17%	122
2015 Q2	$8.89M	Buy	+323,030	New	+$8.61M	0.24%	91

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Oxford Asset Management's IART Position: Q1 2020 in Review

Oxford Asset Management sold out of Integra LifeSciences (IART) in Q1 2020, closing a stake of 18,829 shares — an estimated $1.1M sold.

Oxford Asset Management first reported a position in IART in Q2 2015 and held it in 6 quarters. The position peaked at $8.89M in Q2 2015. 258 funds tracked by Wall St. Rank hold IART as of Q1 2020.

Oxford Asset Management reported no remaining Integra LifeSciences position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 18,829 Integra LifeSciences shares in Q1 2020, an estimated $1.1M.
Oxford Asset Management first reported a position in Integra LifeSciences in Q2 2015 and held it in 6 quarters.
Oxford Asset Management's Integra LifeSciences position peaked at $8.89M in Q2 2015.
258 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.